NCT04529603

Brief Summary

As the detection of small pulmonary nodules continuously grows, the intraoperative localization of small pulmonary nodules is in great demand. The intraoperative localization nowadays is usually done under local anesthesia before surgery. There is a certain rate of failure and complication. The result of our early animal experiments show that the pulmonary surgery marker system can deliver the intraoperative localization safely and precisely under anesthesia, and the average distance between the localization and the simulated lesion is less than 5mm during surgery. Therefore, the safety and feasibility of the system require further evaluation in patients

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Dec 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 24, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 27, 2020

Completed
3 months until next milestone

Study Start

First participant enrolled

December 1, 2020

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2022

Completed
Last Updated

September 2, 2021

Status Verified

August 1, 2021

Enrollment Period

1.7 years

First QC Date

August 24, 2020

Last Update Submit

August 29, 2021

Conditions

Keywords

Lung Neoplasmlocalization of lung nodulesground glass opacitysublobar resection

Outcome Measures

Primary Outcomes (1)

  • Positioning success rate

    When the distance between the LungBrella marker and the Pulmonary nodule is less than 10mm, the marker position is successful. The success rate is the proportion of successful cases to all operation cases

    Immediately after resection

Secondary Outcomes (1)

  • Procedure time

    Duration of procedure

Study Arms (1)

Arm 1

EXPERIMENTAL

LungBrella marker implanted into a predetermined position in the lung assisted by JediVision software and successfully marked the pulmonary nodules which needs to undergo Video-assisted thoracoscopic surgery

Device: LungBrella marker implantation and VATS partial lobe resection

Interventions

The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .

Arm 1

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosis of pulmonary nodule, single nodule operation to be performed and nodule to be located by the decision of chief surgeon. • commit to follow the research procedures and cooperate with the implementation of the whole process research • 1 / 3 of pulmonary nodules are located in the periphery of the lung • signed informed consent with date

You may not qualify if:

  • the target lesion is close to the hilar or large blood vessels • subjects with FEV1 less than 1.2 in lung function • subjects with cardiac function III and cardiac function IV (NYHA, New York) • subjects with uncontrollable acute pleura infection • patients with previous history of thoracic surgery (thoracotomy), plural infection, and plural thickening and adhesion on the affected side • Other factors that investigators disagree enrollment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Hecheng Li

    Ruijin hospitalRuijin Hospital, Shanghai Jiao Tong University School of Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chair of thoracic department

Study Record Dates

First Submitted

August 24, 2020

First Posted

August 27, 2020

Study Start

December 1, 2020

Primary Completion

August 1, 2022

Study Completion

October 1, 2022

Last Updated

September 2, 2021

Record last verified: 2021-08

Locations